Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Jade Biosciences, Inc. (JBIO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $9.96 per share as of 2025-03-31, per its 10-Q filed 2025-04-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2025-04-25
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $9.96.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $10.22.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $12.06.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $12.78.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2025-03-31 | $9.96 10-Q · filed 2025-04-25 |
| 2024-12-31 | $10.22 10-K · filed 2025-03-27 |
| 2024-09-30 | $12.06 10-Q · filed 2024-11-12 |
| 2024-06-30 | $12.78 10-Q · filed 2024-08-12 |
| 2024-03-31 | $12.04 10-Q · filed 2024-05-13 |
| 2023-12-31 | $11.24 10-K · filed 2024-03-25 |
| 2023-09-30 | $13.51 10-Q · filed 2023-11-13 |
| 2023-06-30 | $9.71 10-Q · filed 2023-08-14 |
| 2023-03-31 | $8.41 10-Q · filed 2023-05-15 |
| 2022-12-31 | $7.58 10-K · filed 2023-03-29 |
| 2022-09-30 | $6.44 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.91 10-Q · filed 2022-08-15 |
| 2022-03-31 | $4.98 10-Q · filed 2022-05-16 |
| 2021-12-31 | $4.81 10-K · filed 2022-03-30 |
| 2021-09-30 | $4.35 10-Q · filed 2021-11-15 |
| 2021-06-30 | $2.72 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |